Nurix Therapeutics Inc (NRIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nurix Therapeutics Inc (NRIX) has a cash flow conversion efficiency ratio of -0.154x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.38 Million) by net assets ($372.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nurix Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nurix Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NRIX total debt and obligations for a breakdown of total debt and financial obligations.
Nurix Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nurix Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BASF India Limited
NSE:BASF
|
-0.246x |
|
Magnite Inc
NASDAQ:MGNI
|
0.139x |
|
Jinlongyu Group Co Ltd Class A
SHE:002882
|
0.066x |
|
Israel Corp
TA:ILCO
|
0.038x |
|
SEPLAT ENERGY (DI) NA-50
F:134
|
N/A |
|
Vimian Group AB
ST:VIMIAN
|
0.080x |
|
F&F Co Ltd
KO:383220
|
0.049x |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
0.056x |
Annual Cash Flow Conversion Efficiency for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nurix Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Nurix Therapeutics Inc (NRIX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | $526.99 Million | $-172.58 Million | -0.327x | +19.30% |
| 2023-11-30 | $200.49 Million | $-81.36 Million | -0.406x | +22.88% |
| 2022-11-30 | $303.70 Million | $-159.81 Million | -0.526x | -113.50% |
| 2021-11-30 | $342.30 Million | $-84.36 Million | -0.246x | -89325.95% |
| 2020-11-30 | $290.27 Million | $-80.00K | 0.000x | +99.56% |
| 2019-11-30 | $-9.52 Million | $601.00K | -0.063x | +97.74% |
| 2018-11-30 | $11.35 Million | $-31.68 Million | -2.791x | -- |
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more